Orgenesis CEO to Participate in BIO-Europe Spring 2016 Cell and Gene Therapy Interactive Panel Discussion
GERMANTOWN, MD -- (Marketwired) -- 04/01/16 -- Vered Caplan, CEO of Orgenesis Inc. (OTCQB: ORGS), will participate in an interactive panel discussion at BIO-Europe Spring 2016 in Stockholm, Sweden. Orgenesis is a fully-integrated biopharmaceutical company with a novel therapeutic technology for the treatment of diabetes and a fully owned subsidiary contract manufacturing and development company, MaSTherCell, which is devoted to cell therapy for advanced medicinal products.
Caplan will be speaking April 4, 2016 from 17:15 to 18:15, Level 0 in Room E5. The session, "It's Not a Mirage: The Promise of Cell and Gene Therapy is real," will discuss the reality of diseases having potential to be treated or cured with new advances in the field along with other professionals and leaders in the life science, pharmaceutical and biotechnology industries. The panel will be moderated by Morrie Ruffin of Adjuvant Partners and the other members of the panel will include participants from Biogen, Clayton Biotechnologies, Inc., and Oxford BioMedica.
Caplan, along with other industry leaders, will share insights on strategies in developing, manufacturing and commercializing these life-changing treatments in cell and gene therapy.
BIO-Europe Spring, which attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts, will take place April 4-6, 2016.
About Orgenesis Inc.
Orgenesis is a fully-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing. In addition, through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs). Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. This integrated approach supports Orgenesis' business philosophy of bringing to market significant life-improving medical treatments. For more information, visit www.orgenesis.com.
MaSTherCell SA (Manufacturing Synergies for Therapeutic Cells), a spin-off from ULB (Université Libre de Bruxelles) launched in 2011, is a technology-driven, quality-minded and customer-oriented Contract Development and Manufacturing Organization (CDMO) specialized in cell therapy development for advanced medicinal products. The company is an affiliate of Orgenesis Inc. (ORGS) located in Gosselies, Belgium and provides GMP manufacturing for cell therapy companies. Its mission is to combine expertise, quality systems and infrastructure to help its customers bring highly potent cell therapy products faster to the market. www.masthercell.com
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. Forward looking statements in this press release include that we can successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs); and that our method has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, our limited financial resources; our technology may not perform as well as expected, our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. Readers should refer to the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended November 30, 2015, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.
Released April 1, 2016